| Company Name: |
ENBRIDGE PHARMTECH CO., LTD. |
| Tel: |
+8613812269233 |
| Email: |
tinayang@enbridgepharm.com |
| Products Intro: |
Product Name:N-[(1S,9S)-9-Ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-2-hydroxyacetamide
CAS:1599440-33-1
Purity:98% Package:10mg;0USD|1g
|
|
|
|
|
Dxd manufacturers
- Dxd
-
- $0.00 / 1KG
-
2022-10-14
- CAS:1599440-33-1
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
|
| Product Name: | Dxd | | Synonyms: | Dxd;Exatecan derivative;N-[(1S,9S)-9-Ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-2-hydroxyacetamide;Exatecan derivative for ADC;Acetamide, N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-2-hydroxy-;OQM5SD32BQ;UNII-OQM5SD32BQ;Dxd (Exatecan derivative) | | CAS: | 1599440-33-1 | | MF: | C26H24FN3O6 | | MW: | 493.48 | | EINECS: | | | Product Categories: | | | Mol File: | 1599440-33-1.mol |  |
| Boiling point | 957.9±65.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:40.0(Max Conc. mg/mL);81.06(Max Conc. mM) | | form | Solid | | pka | 11.18±0.40(Predicted) |
| Biological Activity | Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor with IC50 value of 0.31 μM, which can be used as a payload for an antibody-drug conjugate ADC (DS-8201a) targeting HER2. | | in vitro | Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC 50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC 50 s of 1.43 nM-4.07 nM, but the control IgG-ADC (Dxd is the payload) shows no inhibition on the four cell lines (with HER2 expression). DS-8201a (Dxd is the payload) displays significant suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines, with IC 50 values of 26.8, 25.4, and 6.7 ng/mL, respectively, but with no such inhibition on MDA-MB-468 (IC 50 , >10,000 ng/mL). | | in vivo | DS-8201a (Dxd is the payload, 10 mg/kg, i.v.) shows potent antitumor activity in HER2-positive models with KPL4, JIMT-1, and Capan-1 and in HER2 low-expressing ST565 and ST313 models with HER2 IHC 1+/FISH-negative expression. |
| | Dxd Preparation Products And Raw materials |
|